Compare Quanta Services Inc (PWR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quanta Services Inc vs TG Therapeutics Inc — how do they compare? Quanta Services Inc trades at $643.13 (market cap $95.92B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: Quanta Services Inc is far larger — about 11.6× TG Therapeutics Inc's market cap, and Quanta Services Inc pays a 0.07% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PWR | TGTX | |
|---|---|---|
Market Cap | $95.92B | $8.26B |
Sector | Industrials | Health |
52-Week High | $785.24 | $59.06 |
52-Week Low | $372.50 | $26.39 |
Enterprise Value | $101.87B | $8.50B |
Dividend Yield | 0.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PWR (Quanta Services) trades at $639.20, up 1.7% with strong analyst support (75% buy ratings) and a consensus price target of $836.80. The stock shows robust fundamentals with revenue growth from $17.1B in 2022 to $28.5B in 2025, though net margins remain modest at 3.67%. Recent technical indicators are bearish despite oversold RSI readings, with key support at $613. The company benefits from AI infrastructure demand and utility spending, with a record $48B backlog.
Outlook is positive given exposure to grid modernization and AI data center build-out, but high valuation (P/E 86.77) and execution risks pose challenges. Earnings have consistently beaten estimates, with Q2 2026 results due July 30. Institutional sentiment is bullish, though technical weakness near-term warrants caution.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
